Prognostic Role of the Uremic Toxin Indoxyl Sulfate on Vascular and Cardiac Functions During Acute Kidney Injury
Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · Dec 13, 2022
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a substance called Indoxyl sulfate, which builds up in the blood during acute kidney injury (AKI), might affect heart and blood vessel function. Researchers want to find out if higher levels of this uremic toxin could lead to problems with blood circulation and heart health after experiencing AKI. They will measure something called pulse wave velocity (PWV), which helps assess how stiff the arteries are, three months after a patient has had an episode of AKI.
To participate in this study, you need to be over 18 years old and currently hospitalized for moderate to severe AKI without needing dialysis. However, those with severe chronic kidney disease, certain heart conditions, or other specific health issues won't be eligible. If you join the trial, you can expect to have regular assessments to track your kidney and heart health during your recovery. This research aims to improve understanding of how kidney health affects overall cardiovascular risk, which may help in developing better treatments in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age over 18 years old.
- • Patients hospitalized in conventional hospital departments and in intensive care units of nephrology.
- • Patients with moderate to severe AKI (KDIGO 2 or 3) without dialysis.
- • AKI from functional or organic aetiology
- Exclusion Criteria:
- • Patients with severe CKD (GFR\<45ml/min/1.73 m2) or with kidney transplants.
- • Patients with AKI from septic or obstructive aetiology.
- • Patients with AKI from toxic aetiology whose toxic would be also responsable of cardia toxicity.
- • Patients with sepsis or blood inflammation.
- • Patients with severe chronic cardia dysfunction.
- • Patients with arrhythmia or complete heart block.
- • Patients with peripheral artery occlusive disease.
- • Pregnancy.
- • Patients on palliative care.
About Centre Hospitalier Universitaire, Amiens
The Centre Hospitalier Universitaire (CHU) Amiens is a leading academic medical center in France dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on multidisciplinary collaboration, CHU Amiens integrates patient care, education, and research to enhance treatment outcomes and improve patient quality of life. The institution is committed to ethical standards and regulatory compliance in its clinical research endeavors, aiming to contribute significantly to the medical community and the development of new therapeutic approaches. By fostering partnerships with various stakeholders, CHU Amiens strives to translate scientific discoveries into practical applications that benefit patients and healthcare systems alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amiens, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials